Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Business Acquisition [Line Items] | |||
| Net loss applicable to common shareholders | $ (16,395) | $ (12,687) | $ (20,111) |
| Net loss per share-basic and diluted | $ (1.99) | $ (3.61) | $ (41.95) |
| Weighted average shares | 8,246,400 | 3,510,217 | 479,442 |
| X | ||||||||||
- Definition Business acquisition pro forma earnings per share basic and diluted. No definition available.
|
| X | ||||||||||
- Definition Business acquisition pro forma weighted average shares. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|